The National, one of Dubai’s leading newspapers interviewed CELLINK about the latest in bioprinting:

 

“Erik Gatenholm and Dr Hector Martinez, the co-founders of Cellink, a Sweden-based biotech company that commercialises bio-inks for 3D bioprinting of human organs and tissue – the first such company in the world – say the technology will radically change the medical landscape.

“Bioprinting offers a vast range of possibilities to make an impact on different areas such as drug development, organ transplants and cosmetics,” Dr Martinez, who is the firm’s chief technical officer, tells The National.

 

“Bioprinting allows for the precise positioning of multiple cell types within a construct, thus imitating or mimicking the native tissue. Like other biofabrication methods, the integration of capillary size vessels is a big challenge,” adds Dr Martinez.

Bioprinting utilises 3D-printing technology combined with bio-ink to create complex three-dimensional structures. A bio-ink provides a temporary support to the cells while they produce their own extracellular matrix (EM). An EM is a non-cellular component present within all tissues and organs, and provides not only the essential physical “scaffolding” for the cellular constituents but also initiates crucial biochemical and biomechanical cues that are required for normal growth of the various tissues. Bio-inks based on biopolymers such as collagen, gelatin and silk, among others, are known for their favourable biocompatible properties and are useful biomaterials for cell encapsulation and 3D bioprinting.”

 

Continue on to see the entire article.